1. Home
  2. AQMS vs APVO Comparison

AQMS vs APVO Comparison

Compare AQMS & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aqua Metals Inc.

AQMS

Aqua Metals Inc.

HOLD

Current Price

$5.41

Market Cap

20.9M

Sector

Industrials

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$1.07

Market Cap

21.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AQMS
APVO
Founded
2014
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
21.7M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
AQMS
APVO
Price
$5.41
$1.07
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
135.5K
1.1M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$550.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.37
$1.00
52 Week High
$39.40
$109.80

Technical Indicators

Market Signals
Indicator
AQMS
APVO
Relative Strength Index (RSI) 38.29 37.76
Support Level $5.96 $1.00
Resistance Level $7.61 $1.11
Average True Range (ATR) 0.55 0.09
MACD -0.17 -0.01
Stochastic Oscillator 3.19 17.07

Price Performance

Historical Comparison
AQMS
APVO

About AQMS Aqua Metals Inc.

Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: